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Abstract
Background: In Gabon, the impact of intermittent preventive treatment of malaria in infants (IPTi) was not
statistically significant on malaria reduction, but the impact on moderate anaemia was, with some differences
between the intention to treat (ITT) and the according to protocol (ATP) trial analyses. Specifically, ATP was
statistically significant, while ITT analysis was borderline. The main reason for the difference between ITT and ATP
populations was migration.
Methods: This study estimates the cost-effectiveness of IPTi on the reduction of anaemia in Gabon, comparing
results of the ITT and the ATP clinical trial analyses. Threshold analysis was conducted to identify when the
intervention costs and protective efficacy of IPTi for the ATP cohort equalled the ITT cost-effectiveness ratio.
Results: Based on IPTi intervention costs, the cost per episode of moderate anaemia averted was US$12.88 (CI 95%
4.19, 30.48) using the ITT analysis and US$11.30 (CI 95% 4.56, 26.66) using the ATP analysis. In order for the ATP
results to equal the cost-effectiveness of ITT, total ATP intervention costs should rise from 118.38 to 134 US$ ATP
or the protective efficacy should fall from 27% to 18.1%. The uncertainty surrounding the cost-effectiveness ratio
using ITT trial results was higher than using ATP results.
Conclusions: Migration implies great challenges in the organization of health interventions that require repeat
visits in Gabon. This was apparent in the study as the cost-effectiveness of IPTp-SP worsened when drop out from
the prevention was taken into account. Despite such challenges, IPTi was both inexpensive and efficacious in
averting cases of moderate anaemia in infants.
Background
The relationship between malaria and anaemia is com-
plex both in terms of how it can be explained in biome-
dical terms and as part of economic evaluations. Malaria
and anaemia account for a major burden of disease
among sub-Saharan children both independently and in
combination [1]. Anaemia can be caused by many
etiologic factors, including iron and other nutritional
deficiencies. Malaria is clearly an important factor that
may also lead to severe anaemia with a significant risk
of death [2,3]. In areas of high malaria transmission, the
risk of anaemia is highest in infants [4]. Prevention of
malaria infection either by insecticide-treated nets
(ITNs) or drugs (intermittent preventive treatment of
malaria in infants - IPTi - or chemoprophylaxis) have
been shown to significantly reduce infant anaemia in
endemic countries [5-7].
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Anaemia in children less than 5 years old is classified
by the World Health Organization (WHO) into three
categories, according to Haemoglobin (Hb) concentra-
tion in blood: severe (Hb ≤ 5 g/dl), moderate (5 <Hb <
8 g/dl) and mild (8 ≤ Hb < 11 g/dl). Mild anaemia can
signal other problems associated with poor nutrition
rather than being a health problem itself. No disability
weights are associated with mild anaemia in the Global
Burden of Disease [8]. Severe anaemia impairs growth,
motor and mental development and increases the risk of
child mortality [9]. Although the association between
non-severe forms of anaemia and mortality is not
entirely clear [10], mild to moderate anaemia has been
found to be the cause of deficits in child development
[11].
Anaemia is widespread among Gabonese children. A
recent observational study showed that most children
presenting to the health facility with severe falciparum
malaria were less than five years of age (92.3% of 583
cases) and anaemia was the most frequent feature of
severe malaria (67.8% of cases) [12]. In another observa-
tional study in Gabon 69.5% of the malaria-infected chil-
dren aged from 0 to 10 years were moderately to
severely anaemic, with infants at higher risk of develop-
ing severe malarial anaemia [13].
While a large number of clinical trials report the
impact interventions targeting malaria can have on
anaemia [14], very few economic evaluations report this
effect [15,16], with only one attempting to model the
cost-effectiveness of each malaria and anaemia [17]. Ide-
ally a cost-effectiveness analysis would present the
impact of an intervention on all the co-morbidities [18].
This, however, can be a challenge as disability adjusted
life years (DALYs) do not readily lend themselves to
understanding the effect of an intervention on multiple
health outcomes [19]. While individual DALYs for dif-
ferent disease states can be added up, this may not be
appropriate as co-morbidities are not necessarily the
sum of separate DALY disease weightings [19,20]. Many
economic evaluations, including the current one, rely on
natural units such as episodes of a particular illness
averted, but again, this does not provide insights into
the aggregate cost-effectiveness of an intervention for
more than one illness at a time.
In this article, anaemia was explored in the context of
a randomized controlled trial of intermittent preventive
treatment of malaria in infants (IPTi) in Gabon [21].
IPTi involves delivering preventive doses of an anti-
malarial drug during routine Expanded Programme on
Immunization (EPI) visits, regardless of plasmodial
infection status [22,23]. More specifically, the cost-effec-
tiveness of IPTi was investigated in terms of its impact
on moderate anaemia among study infants with and
without malaria. Pooled data from six trials (one each in
Tanzania, Mozambique and Gabon, and three in Ghana)
assessed the protective efficacy (PE) of IPTi with sulpha-
doxine-pyrimethamine (SP) to be 30.3% (CI 95% 19.8%,
39.4%, p < 0.0001) against clinical malaria, 21.3% (CI
95% 8.2%, 32.5%, p = 0.002) against the risk of anaemia,
38.1% (CI 95% 12.5%, 56.2%, p = 0.007) against hospital
admissions associated with malaria parasitaemia, and
22.9% (CI 95% 10.0%, 34.0%, p = 0.001) against all-cause
hospital admissions [14].
In the IPTi country specific trial, Gabonese infants
received SP at 3, 9, 15 months (at the time of the third
dose of diphtheria, pertussis and tetanus - DPT3 - and
measles vaccines plus an extra visit at 15 months). The
impact on malaria was not statistically significant, but
the impact on anaemia was, with some differences
between the intention to treat (ITT) and the according
to protocol (ATP) analysis at 18 months of age [21].
Specifically, ATP was statistically significant, while ITT
analysis was borderline, due in large part to migration
of the infants enrolled in the trial (Figure 1). As IPTi
was not statistically significant on malaria reduction (PE
17%; CI 95% -24%, 44%), the confidence interval of the
incremental cost-effectiveness ratio (ICER) was extre-
mely wide and with a wide negative portion, at US
$29.94 (CI 95% -184.16, 208.75) per DALY averted
based on intervention costs [24]. The statistically signifi-
cant impact of IPTi on anaemia was not included, sug-
gesting that the economic evaluation of IPTi in Gabon
could have been underestimated. The cost-effectiveness
analysis of IPTi in Gabon is presented by focusing on
the impact of the prevention on the reduction of anae-
mia cases and comparing results based on the ITT and
on APT analysis of the efficacy results of the trial at 18
months, that is, three months after the last dose intake.
Methods
Study population
Recruitment for the clinical trial this study refers to was
undertaken at the maternity wards of the Albert
Schweitzer Hospital (HAS) and of the General Hospital
(HG) in Lambaréné, a town of about 25,000 inhabitants,
situated in the Moyen-Ogooué province, in the western
part of Gabon. Lambaréné is the main political, medical
and economic centre of the province. The entomological
inoculation rate in the area is 50 infective bites/person/
year. Malaria transmission is perennial, with little seaso-
nal variation. Bed net use, at least in the peripartal per-
iod, was 80% in the study population during IPTi trial.
However, only a fraction of nets were impregnated, and
insecticide-treated bed net (ITN) coverage was 5% [21].
Efficacy and effectiveness
Mild, moderate and severe anaemia were defined in the
trial according to WHO criteria. Children enrolled were
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given SP or placebo at 3, 9, and 15 months and both
actively and passively followed up. Monthly home visits
for health status assessment, until 30 months of age was
reached, were carried out and in the case of an acute
febrile disease, a finger-prick blood sample was obtained
and a thick blood film examined. In addition, between
home visits, parents were expected to present at the
HAS research unit if the child experienced health pro-
blems. On day 0, before administration and on days 7
and 28 after each drug administration, clinical chemis-
try, full blood count, and thick blood smears were per-
formed [21].
Figure 1 Trial profile of intermittent preventive treatment of malaria in infants in Gabon. Notes: Taken from Grobusch et al [21]; T1 =
treatment 1, T2 = treatment 2, T3 = treatment 3
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Trial data presented results according to the two dif-
ferent perspectives: the intention to treat (ITT) popula-
tion and the according to protocol (ATP) population
[21]. The modified ITT population was defined as all
subjects who correctly received the first drug adminis-
tration within the time limit of one month, regardless of
the status of the other two scheduled administrations.
Therefore, within the ITT population there were chil-
dren who received one treatment, children who received
two treatments and children who received the whole
course of three treatments. The according to protocol
(ATP) population only included subjects who received
all three drug administrations within the specified time
limits and were followed up until 18 months of age. As
a result, 1,011 (85% of the recruited infants) received at
least one dose correctly within the time limits (ITT
population), and 602 (51% of the recruited infants)
received three treatments correctly and were followed
up for 18 months (ATP population). At 18 months the
ITT analysis showed a PE of 22% (CI 95% -1%, 40%), p
= 0.06 while the ATP analysis showed a PE of 27% (CI
95% 2%, 46%), p = 0.04 against at least one episode of
moderate anaemia. This difference between ITT and
ATP efficacies was certainly due to the distinct levels of
adherence to the prevention. Although uneven drop-out
between groups might have played a role, the lack of
data did not allow to verify this hypothesis.
In order to avoid over-optimistic estimates of the effi-
cacy of an intervention, there is currently a general con-
sensus that economic evaluations of trials should be
based on ITT analysis of data generated during clinical/
epidemiological studies [25-29]. In most of the clinical
trials, the primary assessment is based on ITT analysis
and other types of analysis, such as ATP, are secondary
and exploratory. Therefore, economic evaluations based
on such secondary and exploratory analysis of trial data
should be justified [25]. However, under particular cir-
cumstances related to the characteristics of the trial or
in presence of discrepancies between how the interven-
tion is being carried out during the trial and how it is
likely to be implemented in practice, intention to treat
analysis may bias the economic evaluation [26].
In the current study it was found relevant to explore
how different definitions of efficacy may impact on the
economic evaluation of the intervention. Such differ-
ences were substantial in the IPTi trial in Gabon, as
ITT analysis led to non-statistically significant results
and ATP analysis to statistically significant results of the
intervention. In addition, such differences were not just
a statistical artefact as they reflected a relevant socio-
economic phenomenon in the area, such as migration.
The authors were interested in assessing if and how
such differences affected the ICERs. Specifically, to
represent the different efficacies in the economic
evaluation different ICERs were calculated for ITT and
ATP results at 18 months.
In this study, efficacy is defined as percentage reduc-
tion in attack rates in the SP compared to the placebo
group, e.g. protective efficacy of IPTi against moderate
anaemia resulting from the trial. Effectiveness is defined
as number of episodes of anaemia that could potentially
be averted in real life conditions. Specifically, the num-
ber of episodes of moderate anaemia averted was calcu-
lated by multiplying the number of children receiving
the prevention times the protective efficacy of IPTi
against moderate anaemia times the malaria incidence
in the placebo group.
Costings
Intervention costs are presented from the perspective of
the provider only, more specifically the cost to the
health system of providing IPTi was estimated. House-
hold costs associated with accessing IPTi were not
included and thought to be negligible as infants were
already assumed to engage with EPI services. Although
there is research suggesting EPI is not always easily
accessed [30].
The initial costings focused on treating malaria epi-
sodes, therefore, the potential savings to providers (the
health system) and households achieved by averting
anaemia inpatient or outpatient visits were not included.
When comparing ICERs across different interventions,
to limit bias, it is suggested that intervention costs alone
are included, therefore not having included health sys-
tem and household savings from fewer cases of anaemia
should not be seen as a limitation [31]. The implications
of this are discussed in more detail later.
IPTi
The full economic costs of the intervention were based
on a detailed costing of IPTi delivery in Mtwara, South-
ern Tanzania where over 13,976 infants were given IPTi
over the course of two years as part of a phased imple-
mentation study delivering IPTi within routine health
services across five districts [32]. A breakdown of the
cost per dose of delivering SP in Mtwara is given else-
where [33]. Costs included national and district costs
associated with policy change, community sensitization,
behaviour change and communication, drug purchase
and distribution, training, administration of IPTi in
health facilities and management. The costs of delivering
IPTi in Mtwara were adapted to the Gabonese setting to
allow for the costs of delivering IPTi in operational cir-
cumstances and not one generated in more artificial
trial conditions of Gabon. For example, in Gabon the
dispensing of IPTi was undertaken in the research cen-
tre separately from the main health facilities, therefore,
adjustments had to be made to model the cost of IPTi
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within an EPI setting, based on Mtwara resource use.
The SP drug prices from the Gabonese national govern-
ment central medical stores were used.
Tradable and non-tradable components on the South-
ern Tanzanian IPTi study were inflated to US$ 2007
rates. Tradable components of the unit cost were
inflated using US inflation rates. To work out the inter-
national dollar equivalent of buying the same amount of
goods and services in Gabon as compared to Tanzania,
the non-tradable components of the unit costs were
adjusted based on international dollar differences using
purchasing power parity (PPP) adjustment rates [34].
To allow for more accurate ITT and ATP unit costs,
IPTi delivery was split into fixed and variable costs.
Variable costs were associated with resources that were
dependent on the number of IPTi doses received, and
composed of drug purchase and distribution costs and
administration costs of the intervention in the health
facility. All other costs were considered to be fixed, that
is, necessary costs independent of the number of doses
actually administered to infants. Total cost of the inter-
vention was calculated differently for the ITT and the
ATP population. The trial enrolled 1,189 infants, of
which 594 were randomly assigned to the SP group.
The ITT population was composed of 1,011 infants (504
in the SP and 507 in the Placebo) while the ATP popu-
lation, a sub-group of the ITT population, was com-
posed of 602 infants (315 received SP and 287 Placebo),
see Figure 1. Some infants dropped out from the study
between the moment of recruitment and first dose
intake. Infants were recruited and randomized into SP
and control arms at birth and mothers were asked to
take their children to the HAS research unit for visits at
3, 9 and 15 months. EPI vaccinations were given during
the same visits. Of the 594 infants enrolled and rando-
mized in the SP group, the 85% received at least one
dose (N = 504), the 68.5% received at least two doses (N
= 407) and the 53% received the whole course of three
doses (N = 315). The 594 infants randomly assigned to
the SP group were considered as if they were the target
participants of IPTi, therefore, total costs for the target
population of 594 infants were calculated according to
the following formulae:
ITT population = 594 ∗ unit fixed cost + (504 − 407) ∗ unit variable cost ∗ 1 dose SP
+ (407 − 315) ∗ unit variable cost ∗ 2 doses SP + 315 ∗ unit variable cost ∗ 3 doses SP
ATP population = 594 ∗ unit fixed cost + 315 ∗ unit variable cost ∗ 3 doses SP
All costs are presented in 2007 US$.
Cost-effectiveness analysis
Having presented the cost-effectiveness of IPTi on
malaria in Gabon elsewhere [24] below the cost-effec-
tiveness of IPTi on anaemia is shown.
ICERs for IPTi were calculated for the ITT population
(504 infants) and the ATP population (315 infants) by
dividing costs of delivering IPTi by the number of epi-
sodes of anaemia averted. The number of episodes of
anaemia averted in the ITT population was calculated
by multiplying 504 times the protective efficacy calcu-
lated with reference to ITT population times the malaria
incidence in the ITT placebo group. The number of epi-
sodes of anaemia averted in the ATP population was
calculated by multiplying 315 times the protective effi-
cacy calculated with reference to ATP population times
the malaria incidence in the ATP placebo group.
All input variables of the cost-effectiveness model
were expressed as probability distribution. Ranges for
the triangular distributions assigned to each variable
were taken from different sources (Table 1). Triangular
distribution was used to be consistent with Hutton et al
[31] and Conteh et al [24]. Where possible, input vari-
ables were analysed using their confidence intervals
(such as protective efficacies). Where only point esti-
mates were available it was necessary to make assump-
tions on their uncertainty. As in Sicuri et al [35], ranges
were assumed to be equal to ±25% or ±50% of the esti-
mated mean value. Wider ranges were assigned to allow
for more variation to those factors presenting higher
uncertainty in time and space within the country (e.g.
incidence of malaria) [36] and narrower ranges were
assigned to factors assumed to have a lower level of var-
iation (e.g. intervention costs).
Probabilistic cost-effectiveness analysis was performed
through Monte Carlo simulations using @Risk (version
5.0) add-in tool to Microsoft Excel© (Palisade Corpora-
tion, Ithaca, NY, USA).
Threshold analysis was undertaken to compare under
what circumstances ATP and ITT cost-effectiveness
would produce the same cost-effectiveness ratio. Specifi-
cally, threshold analysis explored at what level of inter-
vention costs and protective efficacy the ICER obtained
through the ATP analysis equalled the ICER obtained
through the more commonly used ITT analysis. There-
fore, the ICER resulting from the mostly used ITT ana-
lysis was used as cut-off value for the threshold analysis
of the ATP cost effectiveness, instead of using cut-off
levels employed when ICERs are expressed in terms of
DALYs averted [37].
Results
Costs
For a target population of 594 infants, total costs of the
intervention were US$130.26 for the ITT population
and US$118.38 for the ATP population, see Table 1.
These costs were used as inputs in the cost-effectiveness
model with a range of ±25% as minimum and maximum
value of their assumed probability distribution.
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Cost-effectiveness analysis
As shown in Table 2, in the ITT analysis, the number of
moderate anaemia episodes averted was 16.45 (CI 95%
4.35, 30.26) among 504 infants. The number of moder-
ate anaemia episodes averted was 13.73 (CI 95% 4.70,
24.81) among 315 infants in the ATP analysis.
Using ITT efficacy, the cost per moderate anaemia
episode averted was US$12.88 (CI 95% 4.19, 30.48).
With reference to ATP efficacy, this was US$11.30 (CI
95% 4.56, 26.66). While both mean values and confi-
dence intervals resulted were not very different in the
two types of analysis, the distribution of the cost-effec-
tiveness ratio relative to the ITT analysis were much
more dispersed with a very low minimum and a very
high maximum value of -259.80 and of 1367.16 US$ per
episode averted, respectively (Table 2).
Threshold analysis
Threshold analysis showed that ATP cost-effectiveness
ratio equals the higher level of the ITT cost-effectiveness
ratio (US$12.88 per episode averted) when intervention
costs rise up to US$134 or when protective efficacy drops
down to 18.1%. In other words, the most cost-effective
ATP analysis equals the least cost-effective results of the
ITT analysis when ATP intervention costs increased from
118.38 to 134 US$ or when protective efficacy decreased
from 27.00% to 18.1%. Figure 2 presents these results.
Conclusions
The findings in this paper focus on two topics: (i) the
cost-effectiveness of IPTi at averting anaemia and (ii)
the influence of using ATP as the measure of effect as
opposed to the more commonly used ITT.
Independently of the type of analysis used, this study
assessed that the average cost of a first or only episode
of moderate anaemia averted during infancy/early child-
hood is lower than US$13. Considering the high burden
associated with anaemia in the country, this can be con-
sidered as a very valuable intervention. Specifically, the
cost per case of anaemia averted in the ITT analysis
was, on average, US$12.88. It is difficult to compare this
finding to others which show an effect on anaemia as so
few studies have looked at the cost-effectiveness of
averting anaemia cases; and those which have, tend to
use DALYs, not episodes, as their unit of effectiveness.
The only other study the authors have identified using a
similar approach to this study was an economic evalua-
tion of IPT in schoolchildren undertaken in Kenya, in
which the cost per case of anaemia averted was calcu-
lated at US$29.84 (2006 US$) [38].
Table 1 Input variables used in the probabilistic cost-effectiveness analysis of IPTi-SPa on anaemia
Variable Details of the variables Probability
distribution
Source Range
IPTi-SPa total provider costs in
US$ 2007 for the ITT population
Fixed costs to administer 3 doses IPTi-SPa to a hypothetical target of 594
infants + variable costs to administer 1 dose IPTi-SPa to an actual target of
97 infants, 2 doses to 92 infants and 3 doses to 315 infants
Triangular
(97.70, 130.26,
162.82)
[24,33] ±25%
IPTi-SPa total provider costs US$
2007 for the ATP population
Fixed costs to administer 3 doses IPTi-SPa to a hypothetical target of 594
infants + variable costs to administer 3 doses IPTi-SPa to an actual target of
315 infants
Triangular
(88.78, 118.38,
147.98)
[24,33] ±25%
Cost-effectiveness analysis - input variables
Intention to treat (ITT)
Protective Efficacy 18 months Protective efficacy of IPTp-SPa to avert anaemia at 18 months follow up
(ITT analysis)
Triangular
(-0.01,0.22,0.4)
[21] [21]
Malaria incidence Rate per person-years at risk in placebo group Triangular
(0.08,0.16,0.24)
[21] ±50%
According to protocol (ATP)
Protective Efficacy 18 months Protective efficacy of IPTp-SPa to avert anaemia at 18 months follow up
(ATP analysis)
Triangular
(0.02, 0.27, 0.46)
[21] [21]
Malaria incidence Rate per person-years at risk in placebo group Triangular
(0.075, 0.15, 0.3)
[21] ±50%
aIntermittent preventive treatment of malaria in infants with sulphadoxine-pyrimethamine.
Table 2 Cost-effectiveness of IPTi-SPa to prevent anaemia
in Lambaréné, Gabon
Intervention costs per moderate anaemia cases averted
US $ 2007 95% CIb Min, Max
Intention to treat 12.88 4.19, 30.48 -259.80, 1367.16
According to protocol 11.3 4.56, 26.66 2.97, 97.83
Number of episodes of moderate anaemia averted
N 95% CIb Min, Max
Intention to treat 16.45 4.35, 30.26 -0.44, 42.22
According to protocol 13.73 4.70, 24.81 1.44, 36.73
a Intermittent preventive treatment of malaria in infants with sulphadoxine-
pyrimethamine [(Malaria episodes averted thanks to IPTi were 20 (CI 95% -20,
57) and intervention cost per malaria episode averted was US$ 11.93 (CI 95%
-90.60, 102.87) [24]]
b Confidence Interval
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Using both types of results, ITT and ATP, can give
important information to policy makers. The main finding
of this study is that although IPTp-SP is inexpensive and
efficacious in reducing moderate anaemia, its cost-effec-
tiveness worsens when drop-out is considered. This result
may be intuitive but it is really important in a setting like
Lambaréné where drop-out is primarily caused by migra-
tion and where any type of health intervention is likely to
face the same challenge. The difference between ITT and
ATP allows a comparison of the cost-effectiveness of IPTi-
SP in two scenarios: one in which several of the initial
recipients of the intervention move elsewhere and do not
complete the programme (ITT); another, in which a smal-
ler number of recipients complete the prevention pro-
gramme (ATP). This difference has both cost and health
system/organizational repercussion. The more cost-effec-
tive between the two was the ATP, meaning that total cov-
erage and total adherence constitute the best situation.
However, in a context of migration, reaching complete
coverage and adherence is likely to imply high costs.
In this study, it was considered more appropriate to
report ICERs in terms of the number of episodes of
anaemia averted rather than in terms of DALYs averted.
The magnitude of DALYs averted is particularly sensi-
tive to long-term and severe disabilities and to the case
fatality rate of a disease [39]. IPTi results in Gabon
pointed to a reduction in non-severe cases of anaemia,
which are likely to lead neither to long-term, severe dis-
abilities nor to death. In addition, even if IPTi would
have shown reductions of severe anaemia, which is asso-
ciated to death, there is no evidence in Gabon that
severe anaemia in children leads to death [29]. Without
a sufficiently robust estimate of the anaemia case fatality
rate, any DALY calculation is debatable.
IPTi was more cost-effective at preventing moderate
anaemia when ATP results were used to measure both
efficacy (protective efficacy of IPTi as outcome of the
trial) and effectiveness (episodes of anaemia averted due
to IPTi). ICERs in terms of intervention costs divided by
protective efficacy of IPTi are not reported. However,
Figure 2 Threshold analysis of the cost-effectiveness of IPTi comparing ATP and ITT results. Notes: IPTi = intermittent preventive
treatment of malaria in infants; ATP = According to Protocol; ITT = Intention to Treat
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when analysing efficacy, ATP intervention costs were
lower than ITT intervention costs because the ATP
population was a sub-group of the ITT population and,
therefore, fewer infants were administered with the pre-
vention. In addition, ATP efficacy was higher than ITT
efficacy. Moving from efficacy to effectiveness, effective-
ness was, on average, higher in the ITT than in the ATP
population (ITT cases averted were 16.45; ATP cases
averted were 13.73). This was due to the higher number
of infants included in the ITT compared to the ATP
population. ITT however, still remained less cost-effec-
tive than ATP due to the higher total intervention costs.
The threshold analysis was conducted to explore the
extent that two influential ICER parameters could
change in order for the cost-effectiveness of the ATP
population to equal the more commonly used ITT
population. Findings suggested that intervention costs
should rise from 118.38 to 134.00 US$ for the ICER of
the ATP analysis to equal the ITT one. Since both fixed
unit costs and target population (594 infants) were
assumed to be identical across both types of analysis,
the variable that made the difference in determining
total intervention costs was the number of infants actu-
ally administered with the three doses. For the ATP
ICER to reach the ITT ICER, 435 infants instead of 315
would need to take all three doses in order for the inter-
vention costs to rise up to 134.00 US$. However, the
rise in the number of infants taking three doses would
also have a positive effect on the protective efficacy of
the intervention, thus affecting the cost-effectiveness
ratio at the denominator.
The use of ATP efficacy reduced the uncertainty exist-
ing in the cost-effectiveness analysis, since ATP efficacy
was statistically significant. This reduction in uncertainty
was visible with reference to the minimum and the maxi-
mum value of the cost-effectiveness ratios (Table 2).
Both in this analysis and in the one presented in Conteh
et al [24], ICERs are based on borderline statistically sig-
nificant and statistically non-significant primary out-
comes from the clinical trial in Gabon [21]. There is
some debate about the value of undertaking economic
analysis based on non-significant clinical results. In
accordance with Johnston et al [40], the authors believe
it is worth performing economic evaluation with such
clinical results. Cost minimization, where cost differences
are reported without the calculation of an ICER, was tra-
ditionally used as response to non-significant efficacy dif-
ferences of a trial. However, cost minimization is often
inappropriate as it assumes the trial was powered to
show equivalence of effects, which is rarely the case and
it was not in IPTi trials [41]. Johnston et al [40] advocate
that cost-effectiveness ratios should be calculated even in
absence of significance of efficacy, but uncertainty sur-
rounding ICERs needs to be quantified and highlighted.
While randomized controlled trials (RCTs) provide
crucial information on the efficacy of an intervention
(represented by the protective efficacy of IPTi in this
study), they do not always provide clear information on
the effectiveness (represented here by the actual number
of moderate anaemia cases averted) as they are con-
ducted under atypical conditions. However, RCTs can
give some signs of what coverage might be in a real
world situation. As to be expected, the health benefits
that infants get from the three doses is higher than the
benefits from fewer doses, however, it is evident that in
Gabon adherence to three doses of IPTi spread out over
15 months will prove a challenge.
In Gabon, vaccination coverage, represented by DTP3
coverage, scheduled at 14 weeks was 14% in 1983,
reached a maximum level of 70% in 1995 and dropped
to 45% in 2009, ranking Gabon as the country with the
fourth lowest DTP3 coverage in the African region
(after Chad, Equatorial Guinea and Somalia) [42]. While
migration became a relevant phenomenon from the
early 1980s across Gabon and could have had an impact,
the little information available on this topic does not
explain the changes in coverage entirely [43]. In addition
to migration, the fluctuating EPI coverage and the lack
of the demand for vaccinations has been associated with
side effects, attitudes towards vaccinations, limited
access to providers and bad previous experiences at
mother and child clinics. Gysels et al reported that in
Gabon 80% (184/231) of respondents interviewed about
their use of EPI services and perceptions of IPTi claimed
that shame related to having sick or malnourished
infants, having too many children, or being a young
mother, were common reasons for avoiding routine
clinic visits [44]. All these factors that inhibited demand
for EPI may well have played a role in the fall in uptake
of IPTi.
Although Conteh et al [24], Hutton et al [31] and this
study are economic evaluations based on the same study
trial, the aim of this study was different and subse-
quently the methodology followed differs. In Conteh et
al and in Hutton et al the dropout from the interven-
tion was calculated starting from the intake of the first
dose of SP. In this study, in order to focus on the differ-
ences between ITT and ATP definitions of efficacy, the
drop-out was calculated starting from one step prior to
this. If IPTi was to be introduced, mothers would be
sensitized about the intervention while in the health
facility having just given birth, and would then be
expected to start IPTi on a later occasion in line with
their infant’s vaccination schedule. To reflect this in our
analysis, the drop-out rate was considered to start from
when infants were initially recruited for the trial in the
health facility having just given birth, three months
before the administration of the first IPTi dose.
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The IPTi Gabon trial was the only trial in which cov-
erage dropped to such an extent between the enrolment
and the first dose. Considering coverage loss from the
target population to the first dose is important from a
policy perspective. If preventive health interventions to
infants, at local level, are planned to target newborns,
such plans should take into account the potential migra-
tion of the target population. More research is needed
to explore the migration patterns in Gabon and how
these can shape an individual’s treatment seeking
behaviour.
Cost-effectiveness is an important tool when it comes
to assessing an intervention for possible implementation.
IPTi-SP has shown to be an additional malaria control
tool of value [14] and has, consequently, recently been
added to the WHO’s malaria control instrument portfo-
lio [45]. However, IPTi-SP is recognized to be of use in
particular settings, i.e. in areas of high endemicity, stable
transmission and low SP resistance. For a variety of rea-
sons, such as the efficacy of IPTi bordering on signifi-
cance [21,46] and high levels of SP resistance [47], IPTi-
SP will most likely not be considered as an intervention
of high priority in many countries. Before such country-
level decisions are made, it should be noted that IPTi-
SP can have positive effects in addition to averting
malaria. Seasonal IPTi in areas of unstable transmission
is under evaluation [48] and recent modelling has pre-
dicted IPTi can be cost effective even in settings of low
transmission, seasonality, using short-acting and more
expensive drugs and in conditions of increasing drug
resistance [49]. In addition to averting malaria, the cost-
effectiveness of IPTi at averting anaemia has been
explored in this paper, and other evidence exists to sug-
gest IPTi can have an impact on all cause admissions
[14] and increase EPI vaccine uptake [50]. It is impor-
tant therefore to assess any intervention, not only on
the impact it has on the primary endpoint of a rando-
mized controlled trial, but to also consider the often dif-
ficult to measure, wider, health benefits to the health
system and the individual.
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